Previous close | 10.15 |
Open | 11.70 |
Bid | 7.30 |
Ask | 7.80 |
Strike | 140.00 |
Expiry date | 2024-11-15 |
Day's range | 10.15 - 11.70 |
Contract range | N/A |
Volume | |
Open interest | 23 |
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.